

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Valganciclovir**

**INITIATION – Transplant cytomegalovirus prophylaxis**

Re-assessment required after 3 months

**Prerequisites** (tick box where appropriate)

- ☐ Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis

**CONTINUATION – Transplant cytomegalovirus prophylaxis**

Re-assessment required after 3 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis  
**and**  
☐ Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin

**or**

- ☐ Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis  
**and**  
☐ Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone

**INITIATION – Lung transplant cytomegalovirus prophylaxis**

Re-assessment required after 12 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a relevant specialist, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

**and**

- ☐ Patient has undergone a lung transplant  
**and**  
☐ The donor was cytomegalovirus positive and the patient is cytomegalovirus negative  
**or**  
☐ The recipient is cytomegalovirus positive  
**and**  
☐ Patient has a high risk of CMV disease

**INITIATION – Cytomegalovirus in immunocompromised patients**

**Prerequisites** (tick boxes where appropriate)

- ☐ Patient is immunocompromised  
**and**  
☐ Patient has cytomegalovirus syndrome or tissue invasive disease  
**or**  
☐ Patient has rapidly rising plasma CMV DNA in absence of disease  
**or**  
☐ Patient has cytomegalovirus retinitis

I confirm that the above details are correct:

Signed: ..... Date: .....